BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1039 related articles for article (PubMed ID: 22184384)

  • 1. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
    Lee J; Lim DH; Kim S; Park SH; Park JO; Park YS; Lim HY; Choi MG; Sohn TS; Noh JH; Bae JM; Ahn YC; Sohn I; Jung SH; Park CK; Kim KM; Kang WK
    J Clin Oncol; 2012 Jan; 30(3):268-73. PubMed ID: 22184384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
    Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
    J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer.
    Ustaalioglu BBO; Bilici A; Tilki M; Surmelioglu A; Erkol B; Figen M; Uyar S
    J Cancer Res Ther; 2018 Sep; 14(Supplement):S736-S741. PubMed ID: 30249896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial.
    Yu JI; Lim DH; Ahn YC; Lee J; Kang WK; Park SH; Park JO; Park YS; Lim HY; Kim ST; Kim S; Sohn TS; Choi MG; Bae JM; Nam H
    Radiother Oncol; 2015 Oct; 117(1):171-7. PubMed ID: 26299196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy.
    Jansen EP; Boot H; Dubbelman R; Bartelink H; Cats A; Verheij M
    Br J Cancer; 2007 Sep; 97(6):712-6. PubMed ID: 17848909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
    Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
    Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
    Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).
    Tsuburaya A; Morita S; Kodera Y; Kobayashi M; Shitara K; Yamaguchi K; Yoshikawa T; Yoshida K; Yoshino S; Sakamoto J
    BMC Cancer; 2012 Jul; 12():307. PubMed ID: 22824079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study.
    Kim ST; Kang JH; Lee J; Park SH; Park JO; Park YS; Lim HY; Hwang IG; Lee SC; Park KW; Lee HR; Kang WK
    Eur J Cancer; 2014 Nov; 50(16):2822-30. PubMed ID: 25218337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.
    Lee SS; Kim SB; Park SI; Kim YH; Ryu JS; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
    Jpn J Clin Oncol; 2007 Nov; 37(11):829-35. PubMed ID: 17951334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
    Kwon HC; Kim MC; Kim KH; Jang JS; Oh SY; Kim SH; Kwon KA; Lee S; Lee HS; Kim HJ
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):278-85. PubMed ID: 21114777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial
    Park SH; Lim DH; Sohn TS; Lee J; Zang DY; Kim ST; Kang JH; Oh SY; Hwang IG; Ji JH; Shin DB; Yu JI; Kim KM; An JY; Choi MG; Lee JH; Kim S; Hong JY; Park JO; Park YS; Lim HY; Bae JM; Kang WK;
    Ann Oncol; 2021 Mar; 32(3):368-374. PubMed ID: 33278599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
    Kang YK; Kang WK; Shin DB; Chen J; Xiong J; Wang J; Lichinitser M; Guan Z; Khasanov R; Zheng L; Philco-Salas M; Suarez T; Santamaria J; Forster G; McCloud PI
    Ann Oncol; 2009 Apr; 20(4):666-73. PubMed ID: 19153121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.
    Nishikawa K; Tsuburaya A; Yoshikawa T; Takahashi M; Tanabe K; Yamaguchi K; Yoshino S; Namikawa T; Aoyama T; Rino Y; Kawada J; Tsuji A; Taira K; Kimura Y; Kodera Y; Hirashima Y; Yabusaki H; Hirabayashi N; Fujitani K; Miyashita Y; Morita S; Sakamoto J
    Gastric Cancer; 2018 Sep; 21(5):811-818. PubMed ID: 29488122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy].
    Mihara K; Yamashiro N; Nishiya S; Kemmochi T; Ito Y; Egawa T; Nagashima A
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2358-60. PubMed ID: 25731522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
    Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
    J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
    Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
    Dikken JL; van Sandick JW; Maurits Swellengrebel HA; Lind PA; Putter H; Jansen EP; Boot H; van Grieken NC; van de Velde CJ; Verheij M; Cats A
    BMC Cancer; 2011 Aug; 11():329. PubMed ID: 21810227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
    Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J
    Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
    Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
    Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.